Fibromax | Laboratory research

General Information

The test submission day is Friday.

Blood sample collection in the regions should be carried out on Thursday

Blood sample collection is possible at Tbilisi branches on Thursday or Friday in the first half of the day.

Fibromax test (FibroMax) is a study developed by the company BioPredictive, which combines 5 different non-invasive tests: FibroTest, ActiTest, SteatoTest, NashTest and AshTest.

The Fibromax test is based on an algorithm for evaluating liver damage, which combines the data of serum biochemical markers with the patient's age, sex, weight and height:

1. alpha-2-macroglobulin
2. Haptoglobin
3. Apolipoprotein A1
4. Total bilirubin
5. Gamma glutamyl transferaseGGT
6. აLanin-aminotransferase ALT
7. Aspartate aminotransferase AST
8. Basal blood glucose
9. Cholesterol
10. Triglycerides

Test Fibromax includes 5 different studies:

• Fibrotest measures the degree of fibrosis (METAVIR scale F0-F4)
• act-test measures necrotic-inflammatory activity in patients with chronic hepatitis B and C (METAVIR scale grade A0-A3)
• Steatotest evaluates liver steatosis or the degree of fatness, which is often the basis of ALT and GGT increase (METAVIR scale grade S0-S3)
• NASH-test Assesses the degree of non-alcoholic steato-hepatitis in patients with obesity and dyslipidemia (3 degrees of the Kleiner classification scale)
• ASH-test measures the degree of alcoholic liver damage (H0-H3 degree)

Fibro-test

It was originally developed for patients with chronic hepatitis C, but later it became possible to use it to evaluate the condition of hepatitis B, D, HIV co-infections, alcoholic liver damage and non-alcoholic steatohepatitis.

act-test

It is the only validated laboratory test for necro-inflammatory activity and is used in patients with chronic hepatitis B and C.

Steato-test

It evaluates the degree of steatosis in patients with high metabolic risk: in excessive alcohol users, in chronic carriers of hepatitis B and C. The steatotest assesses the risk of cardiovascular disease associated with steatosis.

NASH-test

(NASH – Non Alcoholic SteatoHepatitis)

It is a possibility to predict non-alcoholic liver damage. The combination of the NASH-test and the fibro-test provides information to assess the patient's metabolic risk.

ASH-test

(ASH – Alcoholic SteatoHepatitis)

It is used to diagnose acute alcoholic steatohepatitis. Liver biopsy is an alternative diagnostic method in patients with alcoholic liver disease.

When is the survey conducted?

The main cause of fibrosis is chronic cellular damage, especially if there is an inflammatory component.

1. B or C viral hepatitis
2. Chronic alcohol consumption
3. Non-alcoholic liver diseases (NAFLDs) due to obesity and/or diabetes
4. autoimmune diseases,
5. Blockage of the bile duct
6. certain medications
7. Hereditary metabolic disorders

Fibromax test FibroMax Provides assessment of the degree of liver fibrosis within a single study:

• Fatty liver (steatotest)
• In case of non-alcoholic steatohepatitis (NASH-test)
• in alcoholic steatohepatitis (ASH-test)

The study is an alternative to liver biopsy and its clinical value has been confirmed by studies.

Preparation of the patient: Research is carried out without fail!

Material for examination: Venous blood

Interpretation of results:

In accordance with the indicators of serum markers, indicators of necrotic-inflammatory activity of liver fibrosis, steatosis, non-alcoholic steatohepatitis and alcoholic steatohepatitis are generated.

Fibrotest

F0 - Absence of fibrosis

F1 - Portal (portal vein) fibrosis

F2 - Progressive fibrosis with rare septal-like ("bridges") formations

F3 - Fibrosis with multiple septum-like ("bridges") formation

F4 - Cirrhosis

Actitest

Degrees of necrotic-inflammatory activity:

A0 - Absence of necrotic-inflammatory activity

A1 - minimal necrotic-inflammatory activity

A2 - moderate necrotic-inflammatory activity

A3 - Severe necrotic-inflammatory activity

Steato-test

S0 - Absence of steatosis/fatness

S1 – Minimal steatosis/fatty (<5% of liver cells)

S2 - Moderate steatosis/fatness (6-32% of liver cells)

S3 - Severe steatosis/fatness (33-100% of liver cells)

Nash-test

N0 - Absence of non-alcoholic steatohepatitis

N1 - Borderline condition of non-alcoholic steatohepatitis

N2 - Presence of non-alcoholic steatohepatitis

Ash-test

H0 - Absence of alcoholic steatohepatitis

H1 – Minimal alcoholic steatohepatitis

H2 - Moderate alcoholic steatohepatitis

H3 - Severe alcoholic steatohepatitis

Test Fibromax is not recommended in patients with:

• Acute hepatitis (characterized by a dramatic increase in ALT)
• Acute hemolysis (the level of haptoglobin decreases)
• Acute inflammatory conditions (alpha-2-macroglobulin increases)
• Extrahepatic cholestasis (bile duct obstruction)
•  Liver transplantation

In patients with acute hemolysis, i.e. Gilbert's syndrome, it is necessary to consult a specialist to interpret the results.